• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    10/15/24 9:59:58 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYRA alert in real time by email
    SC 13D/A 1 ff3997312_13da-tyraboxcap.htm



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    (RULE 13D - 101)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND
    AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
    (Amendment No. 3)*
    Tyra Biosciences, Inc.

    (Name of Issuer)
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

    90240B106
    (CUSIP Number)


    Josh La Grange
    Fried, Frank, Harris, Shriver & Jacobson LLP
    801 17th Street, NW, Washington, DC 20006
    202-639-7497
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)


    October 10, 2024
    (Date of Event which Requires Filing of this Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 90240B106

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
      0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
      0
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    0%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     OO
     
     
     
     





    CUSIP No. 90240B106

    1
    NAMES OF REPORTING PERSONS
     
     
     
    MVA Investors, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    85,939
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    85,939
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     85,939
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     0.2%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     





    CUSIP No. 90240B106

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Aaron I. Davis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    6,534,298
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    6,534,298
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    6,534,298
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    12.4%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     




    CUSIP No. 90240B106

    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    6,448,359
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    6,448,359
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    6,448,359
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    12.2%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, IA
     
     
     
     




    CUSIP No. 90240B106

    1
    NAMES OF REPORTING PERSONS
     
     
    Siddarth Subramony
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    38,300
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    38,300
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    38,300
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    0.1%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     






    With respect to Aaron I. Davis, Siddarth Subramony, MVA Investors, LLC (“MVA Investors”) and Boxer Capital, LLC (“Boxer Capital”), this amendment (this “Amendment No. 3”) further amends and supplements the statement on Schedule 13D filed on September 24, 2021 (the “Original Filing”) by Boxer Capital, Boxer Asset Management Inc. (“Boxer Management”), MVA Investors, Mr. Davis and Joe Lewis with respect to the Common Stock, par value $0.0001 (the “Common Stock”) of Tyra Biosciences, Inc. (the “Issuer”), as previously amended on June 16, 2022 (“Amendment No. 1”) and February 8, 2024 (“Amendment No. 2”). Amendment No. 1 was an original filing for Dr. Subramony. On October 10, 2024, Boxer Capital entered into an investment management agreement (the “IMA”) with Boxer Capital Management, LLC (“BCM”), a registered investment advisor controlled by Mr. Davis. Pursuant to the IMA, Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the securities held in Boxer Capital’s investment portfolio and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. To the extent applicable, the Original Filing, as previously and hereby amended, is hereby adopted by BCM as its original filing on Schedule 13D regarding the Issuer. Capitalized terms used herein but not defined herein shall have the respective meanings defined in the Original Filing, as previously amended. The Original Filing, as previously amended, is further amended hereby only as specifically set forth herein, provided that with respect to any Item amended herein, if such Item is incorporated by reference into any other Item in the Original Filing, as previously amended, such incorporation by reference is also amended hereby. Boxer Capital reports herein that it has ceased to beneficially own more than 5% of the outstanding shares of Common Stock. On or about the day of this filing, Boxer Management and Mr. Lewis are independently amending the Original Filing with respect to themselves; see that filing for any required information pertaining to any of them.
     

    Item 2.
    Identity and Background.

    Item 2 is hereby amended and restated to read as follows:
    This Schedule 13D is jointly filed by Boxer Capital, MVA Investors, Mr. Davis, Dr. Subramony and BCM (collectively, the “Reporting Persons”).
    Boxer Capital is a limited liability company organized under the laws of Delaware. BCM, a limited liability company organized under the laws of Delaware, is a registered investment advisor, providing investment management services to Boxer Capital. Each of Boxer Capital and BCM is primarily engaged in the business of investing in securities.
    MVA Investors, a limited liability company organized under the laws of Delaware, is the independent, personal investment vehicle of certain employees of BCM. MVA Investors is primarily engaged in the business of investment in securities.
    Mr. Davis, a citizen of the United States, is the Chief Executive Officer of Boxer Capital and is a member of and has voting and dispositive power over securities beneficially held by MVA Investors and BCM. With his immediate family, Mr. Davis indirectly owns the membership interests in BCM.
    Dr. Subramony, a citizen of the United States, is a Vice President of Boxer Capital. He is a member of the board of directors of the Issuer.
    By virtue of these relationships, Mr. Davis, Dr. Subramony, MVA Investors and BCM may be deemed to be members of a group, but disclaim the existence of any such group.

        The address of each of Boxer Capital, MVA Investors, Mr. Davis, Dr. Subramony and BCM for purposes of this filing is: 12860 El Camino Real, Suite 300, San Diego, CA 92130.

        Set forth on Schedule A, and incorporated herein by reference, is the (a) name, (b) residence or business address, (c) present principal occupation or employment and (d) citizenship, of each executive officer and director of each of Boxer Capital, MVA Investors and BCM, and (e) name of any corporation or other organization in which such occupation or employment is conducted, together with the principal business and address of any such corporation or organization other than Boxer Capital, MVA Investors or BCM.
        None of the Reporting Persons nor any of the individuals identified on Schedule A to this Schedule 13D has, during the past five years, (a) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (b) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting, or mandating activities subject to, federal or state securities laws or a finding of any violation with respect to such laws.


    Item 3.
    Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended by the addition of the following:

    The disclosure set forth below in Item 4 is hereby incorporated herein.

    Item 4.
    Purpose of Transaction.

    Item 4 is hereby amended by the addition of the following:

    On October 10, 2024, Boxer Management, Boxer Capital and BCM entered into the IMA, pursuant to which Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the shares of Common Stock held by Boxer Capital and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock.


    Item 5.
    Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated to read as follows:
     
    All percentages are based on 52,844,437 shares of the Issuer’s Common Stock outstanding, which is (i) 52,806,137 shares of the Issuer’s Common Stock outstanding as of August 5, 2024 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on August 7, 2024, plus (ii) 38,300 shares of Common Stock subject to options to purchase shares of Common Stock, held by Dr. Subramony, exercisable within the next 60 days.
    (a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 6,572,598 shares of Common Stock, representing 12.4% of the outstanding shares of Common Stock.

    BCM beneficially owns 6,448,359 shares of Common Stock which represents 12.2% of the outstanding Common Stock. MVA Investors beneficially owns 85,939 shares of Common Stock which represents 0.2% of the outstanding Common Stock. Mr. Davis beneficially owns 6,534,298 shares of Common Stock which includes the shares of Common Stock beneficially owned by MVA Investors and BCM and which represents 12.4% of the outstanding Common Stock. Dr. Subramony beneficially owns 38,300 shares of Common Stock which represents 0.1% of the outstanding Common Stock. 
    (b) With respect to any rights or powers to vote, or to direct the vote of, or to dispose of, or to direct the disposition of, the Common Stock owned by the Reporting Persons:
     
    (i)
    Sole power to vote or to direct the vote:

       
        None of the Reporting Persons has the sole power to vote or to direct the vote of any shares of Common Stock of the Issuer.

     
    (ii)
    Shared power to vote or to direct the vote:

       
    BCM, MVA Investors, Mr. Davis and Dr. Subramony have shared power to vote or to direct the vote of 6,572,598 shares of Common Stock.
        
     
    (iii)
    Sole power to dispose or to direct the disposition of:

       
       
    None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock of the Issuer.

     
    (iv)
    Shared power to dispose or to direct the disposition of:

       
       BCM, MVA Investors, Mr. Davis and Dr. Subramony have shared power to dispose or to direct the disposition of 6,572,598 shares of Common Stock.


    (c)   Other than as described herein in Item 4 or transactions previously reported on Form 4, the Reporting Persons have not engaged in any transactions in the Common Stock in the past 60 days.
    (d)   Other than as described herein and except as may result from indirect interests of investors in Boxer Capital, MVA Investors or BCM, no persons other than the Reporting Persons have the right to receive or the power to direct the receipt of dividends, or proceeds of sale of such securities outlined in this report.
    (e)  As described in Item 4, as of October 10, 2024, Boxer Capital ceased to beneficially own more than 5% of the outstanding shares of Common Stock.


    Item 7.
    Material to be Filed as Exhibits.

    Item 7 is hereby amended by the addition of the following:

    Exhibit No.
    Description
    Exhibit 3
     
     
    Joint Filing Agreement, dated October 15, 2024, among Boxer Capital, Mr. Davis, MVA Investors, Dr. Subramony and BCM.
     
     






    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  October 15, 2024.
     
    BOXER CAPITAL, LLC
     
     
     
    By: Boxer Asset Management Inc.
    Its: Manager
     
     
     
    By:
     /s/Paul Higgs
     
     
     
    Name:  
    Paul Higgs
     
     
    Title:
    Director
     
     
    AARON I. DAVIS 
     
         
     
    /s/Aaron Davis
     
      
    Aaron I. Davis, Individually
     
     
     
    SIDDARTH SUBRAMONY
     
         
       /s/ Siddarth Subramony
     
     
    Siddarth Subramony, Individually
     
     
     
    MVA INVESTORS, LLC
     
     
     
    By:
     /s/ Aaron I. Davis
     
     
     
    Name:
    Aaron I. Davis 
     
     
     
    Title:
    Authorized Signatory
     
         
     
    BOXER CAPITAL MANAGEMENT, LLC
     
     
     
    By:
     /s/ Aaron I. Davis
     
     
     
    Name:
    Aaron I. Davis 
     
     
    Title:
    Chief Executive Officer
     


    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)
     In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.0001 par value per share, of Tyra Biosciences, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
    Dated: October 15, 2024.
     
    BOXER CAPITAL, LLC
     
     
     
    By: Boxer Asset Management Inc.
    Its: Manager
     
     
     
    By:
     /s/ Paul Higgs
     
     
     
    Name:  
    Paul Higgs
     
     
    Title:
    Director
     
     
    AARON I. DAVIS 
     
         
     
     /s/ Aaron I. Davis
     
      
    Aaron I. Davis, Individually
     
     
     
    SIDDARTH SUBRAMONY
     
         
         
     
    Siddarth Subramony, Individually
     
     
     
    MVA INVESTORS, LLC
     
     
     
    By:
     /s/ Aaron I. Davis
     
     
     
    Name:
    Aaron I. Davis 
     
     
     
    Title:
    Authorized Signatory
     
         
     
    BOXER CAPITAL MANAGEMENT, LLC
     
     
     
    By:
     /s/ Aaron I. Davis
     
     
     
    Name:
    Aaron I. Davis 
     
     
    Title:
    Chief Executive Officer
     





    SCHEDULE A
    ADDITIONAL INFORMATION CONCERNING THE REPORTING PERSONS
    BOXER CAPITAL, LLC
    The executive officers and directors of Boxer Capital, LLC are set forth below. Each individual’s business address is 12860 El Camino Real, Suite 300, San Diego, CA 92130. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name refers to employment with Boxer Capital, LLC.
     
             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
    Boxer Asset Management Inc.
     
    Manager
     
    Bahamas
    MVA INVESTORS, LLC
    The executive officers and directors of MVA Investors, LLC are set forth below. The individuals’ business addresses are 12860 El Camino Real, Suite 300, San Diego, CA 92130. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name refers to employment with MVA Investors, LLC.
             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
         
    Aaron I. Davis
     
    Manager, Chief Executive Officer
     
    United States
         
    Christopher Fuglesang
     
    Member, President
     
    United States
         

    BOXER CAPITAL MANAGEMENT, LLC
    The executive officers and directors of Boxer Capital Management, LLC are set forth below. Each individual’s business address is 12860 El Camino Real, Suite 300, San Diego, CA 92130. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name of each person refers to employment with Boxer Capital Management, LLC. Boxer Holdings, LP, a Delaware limited partnership, is the sole member of Boxer Capital Management, LLC. Boxer Holdings GP, LLC, a Delaware limited liability company, is the general partner of Boxer Holdings, LP. Mr. Davis is the Manager of, and together with his immediate family owns all of the interests in, Boxer Holdings GP, LLC.

             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
    Aaron I. Davis
     
    Chief Executive Officer; Chief Investment Officer; Manager
     
    United States
     Christopher Fuglesang
      Senior Managing Director
      United States
    Michael Beauchamp
     
    Vice President of Finance
     
    United States



    Get the next $TYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TYRA

    DatePrice TargetRatingAnalyst
    5/21/2025$33.00Overweight
    Piper Sandler
    1/7/2025$28.00Buy
    UBS
    10/18/2024$22.00 → $31.00Neutral → Buy
    BofA Securities
    8/15/2024$33.00Overweight
    Piper Sandler
    12/15/2023$25.00 → $15.00Buy → Neutral
    BofA Securities
    6/30/2023$27.00Outperform
    Wedbush
    2/3/2023$17.00Outperform
    Oppenheimer
    6/23/2022$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $TYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tyra Biosciences to Participate at Upcoming Investor Conferences

      CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Conference, May 13-15, 2025Format: Fireside chat and one-on-one investor meetingsPresentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PTLocation: Las Vegas, NVJefferies Global Healthcare Conference, June 3-5, 2025Format: One-on-one investor meetingsLocation: New York, NYUBS Biotech 1x1 Symposium, June 24,

      5/12/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

      - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif., May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. "In 2025, we are focus

      5/8/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

      - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif., March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today rep

      3/27/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

      CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global ex

      1/29/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

      -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cance

      1/10/25 8:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

      - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30

      11/7/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      12/6/24 9:30:49 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/19/24 9:31:34 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

      SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/14/24 5:47:01 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $19,836,066 worth of shares (1,220,681 units at $16.25) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/13/24 5:00:07 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan bought $151,954 worth of shares (9,500 units at $16.00), increasing direct ownership by 284% to 12,849 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/1/24 4:22:45 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Tyra Biosciences with a new price target

      Piper Sandler resumed coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $33.00

      5/21/25 9:01:58 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Tyra Biosciences with a new price target

      UBS initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $28.00

      1/7/25 8:31:57 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences upgraded by BofA Securities with a new price target

      BofA Securities upgraded Tyra Biosciences from Neutral to Buy and set a new price target of $31.00 from $22.00 previously

      10/18/24 7:41:59 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Tyra Biosciences Inc.

      8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/29/25 4:22:58 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tyra Biosciences Inc.

      EFFECT - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/19/25 12:15:16 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.

      SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)

      5/14/25 4:05:29 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Financials

    Live finance-specific insights

    See more
    • Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

      - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann

      10/24/24 6:21:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

      CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste

      10/23/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

      - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima

      3/1/23 7:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Harris Todd was granted 1,241 shares, increasing direct ownership by 0.09% to 1,357,168 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:12 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan was granted 1,238 shares, increasing direct ownership by 10% to 14,087 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kjellson Nina S sold $74,324 worth of shares (5,401 units at $13.76) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      2/7/25 4:43:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care